DexCom Gains Pre-Market Traction on Financial Figures, Bullish Views
- July 28th, 2023
- 517 views
DexCom, Inc. (Nasdaq: DXCM) delivered strong results in the second quarter of 2023, with earnings per share (EPS) of $0.34 and revenues of $871.30 million, surpassing the consensus estimate of $0.23 EPS on revenue of $841.62 million.
In response to the robust performance, the company raised its fiscal full-year 2023 revenue guidance to between $3.50 billion to $3.55 billion, up from the previous range of $3.40 billion to $3.52 billion. Analysts had expected revenue of $3.50 billion for the period.
Furthermore, investment firms Baird and Raymond James upheld their positive outlook on DexCom. Baird maintained an Outperform rating and raised the price target from $145 to $153, while Raymond James maintained a Strong Buy rating and increased the price target from $140 to $154.
In pre-market trading, $DXCM surged by $4.95 (+3.83%) to reach $134.31.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Tags
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login